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Abstract
Background: Infections caused by dengue virus are a major cause of morbidity and mortality in tropical and subtropical
regions of the world. Factors that control transition from mild forms of disease such as dengue fever (DF) to more life-
threatening forms such as dengue hemorrhagic fever (DHF) are poorly understood. Consequently, there are no reliable
methods currently available for early triage of DHF patients resulting in significant over-hospitalization.
Methodology/Principal Findings: We have systematically examined the proteome, cytokines and inflammatory markers in
sera from 62 adult dengue patients (44 DF; 18 DHF) with primary DENV infection, at three different times of infection
representing the early febrile, defervescence and convalescent stages. Using fluorescent bioplex assays, we measured 27
cytokines in these serum samples. Additionally, we used multiple mass spectrometry methods for iTRAQ-based comparative
analysis of serum proteome as well as measurements of protein adducts- 3-nitrotyrosine and 3-chlorotyrosine as surrogate
measures of free radical activity. Using multiple methods such as OPLS, MRMR and MSVM-RFE for multivariate feature
selection and classification, we report molecular markers that allow prediction of primary DHF with sensitivity and specificity
of .80%.
Conclusions/Significance: This report constitutes a comprehensive analysis of molecular signatures of dengue disease
progression and will help unravel mechanisms of dengue disease progression. Our analysis resulted in the identification of
markers that may be useful for early prediction of DHF during the febrile phase. The combination of highly sensitive
analytical methods and novel statistical approaches described here forms a robust platform for biomarker discovery.
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Introduction
Infection with dengue virus (DENV) causes a spectrum of
clinical manifestations ranging from mild dengue fever (DF) to the
potentially lethal dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS) [1]. In humans, the major cellular targets of
dengue appear to be dendritic cells of the skin, macrophages and
monocytes [2]. Dengue is endemic to the tropical and sub-tropical
regions of the world, which are home to over half the population of
the world as well as being popular tourist destinations. It has also
emerged in new areas such as south Florida and Mediterranean
France. With a significant proportion of the world population at
risk of infection annually, coupled with the absence of a licensed
vaccine, dengue is emerging as a global health concern.
The majority of dengue patients recover uneventfully after 5–7
days of acute illness. In a small proportion of patients, however,
the initial febrile period is followed by a rapid onset of vascular
leakage, thrombocytopenia and hemorrhage indicating DHF. The
continual loss of intravascular volume from plasma leakage can
very rapidly lead to hypotension and cardiovascular collapse
which, if not carefully managed, can result in death. In the absence
of an effective antiviral drug, the management of dengue patients
is primarily supportive. Early recognition of patients with plasma
leakage is thus critical for the initiation of appropriate fluid
management to prevent onset of hypovolemic shock. However,
because these symptoms become evident only in the critical phase
of infection, it is currently not possible to distinguish DF and DHF
accurately during the early stages of illness, when the disease is less
well differentiated [3].
The mechanisms that trigger transition from mild DF to more
life threatening DHF are poorly understood, hampering early
classification of dengue patients who will progress to DHF. This
not only delays treatment but frequently results in the over-
hospitalization of patients contributing significantly to the financial
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burden imposed by dengue [4,5]. The availability of reliable
markers that predict DHF during the early stages of infection
could be useful in triaging patients for management.
In the last decade, numerous efforts have been made to identify
serum markers that may predict severe dengue disease, with an
emphasis on cytokines [6]. A number of studies propose that
innate immune cytokines (e.g. IFN-a, IL-8) are elevated during the
early febrile phase while adaptive immune cytokines (e.g. TNF-a,
IL-10, IFN-c) appear to increase during the defervescence phase of
dengue infection [6]. Several factors have traditionally limited the
usefulness of these studies in biomarker development. Firstly, the
highly variable nature of patient cohorts (e.g. pediatric versus
adults; ethnicity) used makes it difficult to compare the results of
these various studies. Secondly, most studies have examined ‘case
versus control’ type of sample population instead of longitudinal
studies to distinguish ‘predictors’ from ‘indicators’. Finally, a lack
of follow-up in larger population base to test the prognostic
potential of proposed markers limits their clinical application.
The early dengue infection and outcome (EDEN) study in
Singapore prospectively recruits and follows-up adult dengue
patients in Singapore through early febrile, defervescence as well
as convalescence stages [7] of the disease. This makes this
longitudinal study highly suited for the identification of prognostic
markers of severe dengue disease. In this study, we report a
systematic characterization of serum cytokines, proteome, and
markers of macrophage and neutrophil activity in a subset of adult
dengue patients with primary dengue infections obtained from the
EDEN cohort. In addition to identifying molecular signatures of
disease progression, we describe a comprehensive multivariate
statistical analysis to identify serum markers for early prediction of
DHF.
Methods
Dengue patient recruitment, sample collection and
clinical evaluation
The EDEN study is a multi-center longitudinal study of adult
febrile infections that was carried out at a number of clinics island-
wide in Singapore. Enrollment of eligible individuals was based on
written informed consents and the protocols were approved by the
National Healthcare Group (DSRB B/05/013). The study
protocols have been described earlier [7]. In brief, adult patients
(.21 years) presenting with acute onset fever ($38.0uC for less
than 72 hours) without rhinitis or other clinical alternatives were
included in the study. Initial dengue diagnosis and viremia levels
were determined by real time RT-PCR using a previously
described method [8]. This was followed by serology and
subsequent serotyping by virus isolation and immunofluorescence
using serotype specific monoclonal antibodies (ATCC: HB46-49).
Venous blood samples were also collected at fever day 4 to 7 (visit-
2) and weeks 3 to 4 (visit-3), aliquoted and frozen at280uC. ‘Fever
day’ here refers to number of days post onset of fever.
Classification of DF or DHF was made based on the guidelines
provided by the WHO [9]. In brief, acute febrile patients positive
for dengue with one or more of the following: headache, retro
orbital pain, myalgia, rash, leucopenia, hemorrhage were classified
as DF while patients with fever lasting 2–7 days combined with
bleeding, thrombocytopenia (,100,000/mm3) as well as evidence
of plasma leakage shown by a 20% or greater rise in hematocrit
relative to the blood sample obtained at convalescence or pleural
effusion on chest X-ray were classified as DHF. Of the 133 dengue
patients that were finally enrolled in this study (September 2005–
October 2006), 62 patients (44 DF, 18 DHF) tested negative for
dengue IgG antibodies in the acute sera, using a commercial
ELISA kit (PanBio, Brisbane, Australia). These patients were
deemed to have primary DENV infection, all of which were
included in this study.
A detailed hematological and virological analysis was performed
and a subset of 15 clinical indicators was selected for our statistical
analysis. These included white blood cell count (WBC), red blood
cell count (RBC), blood hemoglobin (HGB), hematocrit (HCT),
macrophage cell volume (MCV), MCH, MCHC, platelet count
(PLT), lymphocyte percentage (LYMPH%), lymphocyte count
(LYMPH), mixed cell distribution (MXD), neutrophil percentage
(NEUT%), neutrophil count (NEUT), red blood cell distribution
width-coefficient of variation (RDW-CV), and viral titers. Addi-
tionally, we used plasma samples from 50 asymptomatic healthy
army recruits collected during their annual physical examination
in Singapore as controls in our analyses. A comparison of
cytokines in dengue patient sera with healthy plasma is shown in
supplementary data (Figure S1 and Table S1). This study was
approved by the National University of Singapore Institutional
Review Board and samples were collected with individual
informed written consents (see checklist S1).
Fluorescent bead based measurement of cytokines and
serum proteins in patient sera
Cytokine measurements were performed with 12.5 ml sera in
duplicates using the Bioplex 27-plex human cytokine kit from
BioRad as per manufacturer’s instructions. The standard curves
were optimized automatically by the software (Bioplex manager)
and verified manually. The Bioplex manager software was used to
calculate cytokine concentrations and only measurements that
showed a coefficient of variability (CV) of,10% were included for
further analysis. Levels of interferon-induced cytokine IP-10 in
30% of the dengue patient samples during visit-1 were above
upper limit of detection. We repeated the analysis after diluting the
serum 100 fold for this subset of samples. Six of the visit-1 samples
in DF group and 3 in DHF group still had very high levels of IP-10
and for the statistical analyses, we included these as missing values
since levels of other cytokines for these samples were within
detectable range. Measurement of 9 acute phase proteins was
performed using the Bioplex Pro Acute phase multiplex kit
(BioRad laboratories) as per manufacturer’s instructions. Two
different dilutions of sera were used-1:1000 for ferritin (FT), serum
Author Summary
While the majority of patients who exhibit febrile dengue
infection recover within a week, a small proportion of the
patients progress to develop severe symptoms that can be
life-threatening if not managed in a hospital setting.
Because there is no method to accurately identify this
subgroup of patients, many dengue patients are hospital-
ized unnecessarily, which causes significant burden to the
healthcare system. In our study, we have systematically
measured a large number of molecules including cytokines
and serum proteins in blood samples from a dengue
patient cohort using highly sensitive mass spectrometry-
based methods. We have further developed novel statis-
tical methods that allow us to identify small panels of
measureable blood markers, which can distinguish dengue
patients that develop milder, self-limiting form of the
disease from those that progress to develop severe
symptoms. Because these markers can be applied within
48–72 hours of onset of febrile symptoms, we expect them
to be useful for early classification of severe dengue
disease.
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amyloid A2 (SAA), procalcitonin (PCT), tissue plasminogen
activator (tPA), fibrinogen (FB) and 1:100,000 for alpha-2-
macroglobulin (A2M), haptoglobin (HPT), C-reactive protein
(CRP) and serum amyloid P (SAP).
Quantitative analysis of serum proteome
Sample pooling, iTRAQ labeling and OFFGEL peptide
separation. We performed an isobaric tagging for accurate
quantitation (iTRAQ) method for multiplexed analysis of serum
proteome in dengue patients. For this, we first pooled serum
samples (5 ul each) from 10 DF and 10 DHF patients selected
randomly from our study population. The same groups of patients
were followed for pooling of the samples from each visit resulting
in a total of 6 pools (3 from DF and 3 from DHF). From
10 microliters of each pooled sample, albumin and immunoglob-
ulins were depleted using the Vivapure anti HSA/IgG kit
(Sartorius-stedim, USA). Following concentration and desalting,
the protein concentration was measured in each sample using the
BCA method in a kit [10] (Pierce chemical co. USA). Seventy-five
micrograms of protein was subjected with trypsin digestion at a
ratio of 1:80 (trypsin : protein) followed by labeling with isobaric
tags using the 4-plex-iTRAQ kit (AB Sciex Pte Ltd, USA) as per
manufacturer’s instructions. The peptides from DF visit-1 pool
were labeled with 115 reporter ions while those from visits 2 and 3
were labeled with 116 and 117 reporter ions respectively. Peptides
from an independently processed control serum sample (30 day
convalescent sample from a randomly selected dengue patient in
our cohort) were labeled with 114 reporter ions. A similar strategy
was used in a separate 4-plex experiment for DHF samples but
using the same reference ions (114) as the DF samples. The
individually labeled peptide samples from each group were pooled
and multiplexed peptide samples were desalted using a C-18 SPE
cartridge (Agilent technologies), resolved by isoelectric focusing on
a pH 3–10 strip (GE healthcare) on an OFFGEL fractionator
(Agilent technologies). The resolved peptides were collected in 12
fractions, dried and dissolved in 15 ml of 2%ACN/0.1%TFA.
LC MS/MS analysis. The samples were analyzed on an
Agilent 6520 Accurate-mass QTOF-LC/MS system equipped
with a 1200 series HPLC-Chip/MS system. We separated
peptides on a HPLC-Chip with 75 um6150 mm analytical
column HPLC-Chip and a 160 nL enrichment column. Three
injections (1 ul each with approximately 2 ug peptides) of each
sample were separated using a 60 min gradient (5% at 0 min 10%
2 min, 50% 42 min 80% 42–50 min, 5% 50–60 min) with
Water/0.1%formic acid as aqueous phase and 95%acetonitrile/
5%water/0.1%formic acid as organic phase at flow rates of
300 nL/min. Peptides eluting from the LC were injected online
into the accurate-mass QTOF and examined in positive ion mode
with the following settings for MS mode: 4 spectra/sec, m/z 110–
2300, MS/MS mode: 8 spectra/sec, m/z 60–1097 with drying gas
flow 5 L/min, 325degC, collision energy slope 3, intercept 2.5,
and a capillary voltage of 1950.
Data analysis. Spectrum Mill software (Agilent Technolo-
gies) was used for protein identification and quantitation of
iTRAQ reporter ion intensities. A minimum peptide score of 8
and a protein score of 10 was used to generate protein lists by
searching against the Swissprot database. These thresholds were
determined by comparing results from searching the Swissprot
database and a reversed random database to identify error rates.
The peptide and protein score thresholds indicated above ensured
a false discovery rate of ,5% in protein identification. Only
proteins identified with two or more peptides were selected for
relative quantification. A global weighted threshold for fold change
was determined by comparing the ratio of summed intensities of
each reporter ion for all peptides (115/114- 1.05; 116/114- 0.96;
117/114- 1.09) and then the intensities of each peptide ratio were
further corrected by this factor. This weighted threshold was
essential to make sure the fold changes observed were not simply
due to an overall bias towards one or more reporter ion. Finally,
fold change for each protein was calculated as a ratio of summed
intensities of reporter ions across different peptides per protein.
Measurement of serum chlorotyrosine and nitrotyrosine
Nitrotyrosine (NT) and chlorotyrosine (CT) in human serum
were measured by a liquid chromatography-triplequadrupole MS
method. Briefly, 2 mg of serum protein was spiked with 4 pmol
internal standards (IS) L-3-chloro-[13C9,
15N]-tyrosine and L-3-
nitro-[13C9,
15N]-tyrosine, and digested in the sodium acetate
solution 0.1 M (pH 7.4) with 0.4 mg pronase E (freshly treated by
the size-exclusive micro bio-spin column). The mixture was
incubated at 50uC for overnight (16 hrs.) and filtered by
Vivospin500 3KMW centrifuge filter at 15,000 rpm to remove
undigested protein. The amino acids were further purified by
Agilent 1200 series HPLC system (Waldbronn, Germany) on an
Xbridge TM Phenyl column (3.5 mm, 4.6650 mm, Waters,
Milford, MA). The fractions containing nitrotyrosine and chlor-
otyrosine, together with internal standards, were collected and
dried by SpeedVac for subsequent LC/MS/MS analysis. Subse-
quent mass spectrometry analysis of target compounds involved
separation on an Xbridge TM Phenyl column (3.5 mm,
1.06100 mm, Waters, Milford, MA) online injection into an
Agilent 6460 triple quadrupole mass spectrometer. Two microli-
ters of each sample was injected and eluted by isocratic 25%
methanol (0.1% formic acid) for 13 min at 15 mL/min. CT along
with IS were analyzed by regular multiple reaction monitoring
(MRM) as follows: 216/170 (CT) and 226/179 (CT, IS). NT along
with IS were measured by modified MS3 based in-source
fragmentation as follows: 181/117 (NT) and 190/125 (NT-IS)
by elevating the potential to 135 V at the ion source. The limits of
quantitation achieved were 8.1 and 7.3 nM for CT and NT,
respectively.
Statistical analysis
Clustering of time courses and confidence
testing. Overall, our dataset (cytokines, serum proteins and
protein adduct measurements) had a largely non-gaussian
frequency distribution (D’Agostino and Pearson Omnibus nor-
mality test, Graphpad prism), and were unbalanced with unequal
sample sizes between different groups necessitating non-paramet-
ric data normalization and hypothesis testing where indicated. K-
means clustering was performed on time courses of measurements
using the Unscrambler-X statistical software package (CAMO
software, Oslo, Norway). In order to perform K-means clustering
of cytokine levels over different time points, mean cytokines levels
(population means) were first normalized by dividing the values by
their mean (mean of three time points) to bring all cytokine values
within range. It was empirically found that K=4 gives the best
inter-class variances. In a second step, the members across
different clusters were compared manually to determine if the
fold changes of cytokines between visit 1 and 2, and visit 2 and 3
were statistically significant (p,0.05); if not, the clusters were
merged. This resulted in three broad clusters as shown in the
results section. For comparison of individual cytokines, serum
proteins and protein adducts at different time points or between
DF and DHF groups, one-way ANOVA with a non-parametric
Kruskal-Wallis test was used. Final diagnosis for this test included
DF vs. control, DHF vs. control and DF vs. DHF within each time
point. A Dunn’s multiple comparison post-test comparing all pairs
Serum Markers of Dengue Disease Progression
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of datasets was used to test the null hypothesis at a significance
threshold p value,0.05. A two-way ANOVA test followed by a
bonferroni correction was used to determine if increased
proportion of DENV serotype-2 in DHF group compared to DF
group affected the outcome of hypothesis testing between them for
all cytokines and clinical parameters and was not found to be
significant (at p,0.05). Correlation analysis was performed using
the Pearson’s correlation matrix on the Graphpad prism software
and where indicated, the correlation coefficient and the signifi-
cance values are reported. For all the data analysis performed in
this study, p,0.05 was considered significant.
Selection of predictive markers. We used multiple feature
selection approaches to select subsets (that is, the predictive
markers) that give the highest predictive accuracy. To rank the
ability of clinical and cytokine measurements to classify different
types of dengue populations (e.g. DF vs. DHF), three feature
selection strategies were used: the orthogonal projection least
squares (OPLS), the multiple-support vector machine-recursive
feature elimination (MSVM-RFE), and the maximum relevance
minimum redundancy (MRMR) criterion. The OPLS finds
features that maximize the correlation between input features
and class labels (X) which has been used extensively for biological
classification, for example microarray data analysis [11]. Multiple-
support vector machine-recursive feature elimination (MSVM-
RFE) selects relevant input features, based on the weights of SVM
classification, and has been used for selection of genes for sample
classification from microarray data [12,13]. The maximum
relevance minimum redundancy (MRMR) criterion ranks features
based on the maximum relevancy with the target populations
while minimizing the redundancy among all the features [14]. The
MRMR was implemented using two measures: the mutual
information quotient (MRMR-MIQ) and the mutual information
difference (MRMR-MID). Furthermore, the samples were uni-
formly bootstrapped with replacement and the average rank was
computed to stabilize the outcome of feature ranking.
We used the radial basis function (RBF) kernel-based support
vector machines (SVM) to evaluate prediction accuracy of each
selected subset. The original dataset was partitioned into training
and testing datasets, randomly for 1000 times. The regularization
and scaling parameters of the RBF kernel SVM were estimated
using the leave-one-out cross-validation (LOO-CV) on the training
datasets by choosing values selected from a grid formed by the
values of regularization and scaling parameters. The hyper-
parameters were determined by optimizing the weighted sum of
errors in different classes. Here, the weights were used to handle
the unbalanced sample sizes of different classes: the error in each
class was weighted by the percentage number of samples of
another class. The features were then selected by minimizing the
same weighted error on the test dataset. This type of analysis was
performed using OPLS+SVM, MRMR-MID, MRMR-MIQ, or
MSVM-RFE after scaling and standardization as preprocessing of
data samples. The performances of features selected by different
methods were determined by the area under the curve (AUC) of
receiver operating characteristics (ROC). An AUC value of .0.85
was used as a threshold for good predictive performance.
Thereafter, one and two-sided two-sample t-test were performed
on the best bootstrapped accuracy and the accuracies produced by
the features selected by other methods. The features selected by
the top-performing method and other methods that had no
significant difference (p-value.0.05) in accuracies were combined
into a common feature set as the top-performing subset. The
averages for sensitivity, specificity and AUC of the top-performing
feature subsets are reported. A MATLAB script was prepared to
run all of the above types of analyses and run on the MATLAB
software package. A schematic diagram detailing the workflow for
this statistical process is shown in Figure S3.
Results
Serum cytokine profile and clinical features of primary
dengue infection
We selected 62 adult dengue patients from the EDEN cohort, of
which 44 were diagnosed as DF, and 18 as DHF. The patients
selected in DF and DHF groups had similar age and ethnic
distribution (Table 1). Serotyping analysis indicated that DENV
serotypes-1 and -3 were the most common, followed by serotype-2,
while no serotype-4 was present. Average duration between fever
onset and first sample collection was ,48 hours, and the average
duration between samples were ,80 hours (visit 1 & 2) and
,21days (visit 2 & 3) respectively (Table 1).
We examined the key clinical indicators commonly used for the
diagnosis of DHF. Blood platelet count dropped significantly from
febrile phase to defervescence in both DF and DHF patient groups
with DHF patients exhibiting significantly (p,0.05) lower platelet
levels during defervescence (visit-2) than DF patients (Figure 1A).
DHF patient groups also exhibited significantly (p,0.05) lower
WBC and lymphocyte counts especially during defervescence
(Figure 1B &C). Viral titer measured at visit-1 was higher in DHF
patients (Figure 1D) consistent with several previous studies that
have reported higher plasma viral loads in DHF patients [15,16].
Our study population thus recapitulated most of the hallmark
Table 1. Characteristics of dengue patient study population.
Patient Groups Serotype Age Race Blood sampling Time *
DF (n = 44) D1 (24, 54%) 39613.02 Chinese (36, 81.8%) 46620 hours (visit-1)
D2 (1, 2.3%) Indian (2, 4.5%) 73631 hours (Vist-2)
D3 (19, 43%) Malay (2, 4.5%) 1665 days (visit-3)
D4 (0) Others (4, 9.0%)
DHF (n = 18) D1 (12, 66.6%) 40614.08 Chinese (14, 77.7%) 42622 hours (visit-1)
D2 (3, 16.6%) Indian (2, 11.1%) 77632 hours (Vist-2)
D3 (3, 16.6%) Malay (1, 5.55%) 20612 days (visit-3)
D4 (0) Others (1, 5.55%)
*Average6SD time from fever to phlebotomy (visit-1), between visits 1 & 2 (visit-2) and between visits 2 & 3 (visit-3). DF- dengue fever; DHF dengue hemorrhagic fever;
D1-dengue serotype-1; D2-dengue serotype-2; D3-dengue serotype-3, D4-dengue serotype-4.
doi:10.1371/journal.pntd.0001887.t001
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clinical features of dengue progression in DF and DHF during the
early febrile, defervescence and convalescence stages of infection.
We measured the levels of 27 serum cytokines in our dengue
patient cohort, using a multiplex assay. A majority of cytokines was
maximally elevated in dengue patients during the early febrile
phase (visit-1) of infection (Table S1, Figure S1). These included
IL-1ra, IL-4, IL-7, IL-8, IL-10, IL-12, Eotaxin, G-CSF, IFN-c, IP-
10, MCP-1, MIP-1b and VEGF. Cytokines IL-1b, IL-5, IL-6, IL-
9, IL-12, IL-17 and FGF-basic, remained elevated during
defervescence (visit-2) and convalescence (visit-3) stages. When
Figure 1. Clinical laboratory features and cytokine responses in primary dengue infections. A–C Hematological analysis of patient blood
samples (DF (n = 44) and DHF (n = 18)) showing platelet count (A), white blood cell count (B) and lymphocyte count (C). Mean (with upper standard
deviation shown in error bars). Statistical confidence was analyzed by ANOVA kruskall-wallis test (DF vs DHF: *p,0.05, **p,0.01, NS- not significant).
(D) Viral titers measured by RT-PCR in the febrile stage shown as mean of genomic copies per ml with p values from two-sided student’s T-test. E. K-
means clustering analysis of temporal profile of 23 cytokines measured at different stages of infection in 62 dengue patients (44 DF+18 DHF). F.
Identity of cytokines in each cluster. Cluster-1 consisted of a single cytokine- IP-10, and is not shown in the figure. Cytokines that clustered differently
in DF and DHF groups are labeled by asterisk in F.
doi:10.1371/journal.pntd.0001887.g001
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compared with plasma samples from an independent cohort of
healthy individuals, cytokines IP-10, VEGF and PDGF-BB were
found to be elevated .20 times over controls during the febrile
phase of infection, while IL-4, IL-9, IL-10 and IL-1ra were
elevated by 10–20 times over controls (Table S2). Cytokines IL-6,
IL-7, IL-8, Eotaxin, G-CSF, IL-17 and MIP-1b were elevated 4–8
fold (Table S2). These values may however be an overestimation
of the actual changes since an independent cohort may not be an
ideal control for the study population.
To identify temporal patterns in cytokine flux in patient sera, we
performed K-means clustering to group cytokines in DF patients
exhibiting similar patterns across the three stages of disease as
detailed in the methods section. The cytokine IP-10 was the sole
member of cluster-1 (Figure 1E) with very high levels during the
febrile phase followed by a rapid decline to near control levels at
convalescence. A majority of cytokines fell into a second cluster
(Figure 1E and F, Cluster-2) that exhibited a peak at the febrile
phase but declined modestly, with levels remaining significantly
higher than controls even at the late convalescent stage (visit-3). A
third cluster of 7 cytokines (Figure 1E and F, Cluster-3) increased at
febrile phase and decreased during defervescence but increased
again to peak levels during late stages (visit-3). While overall
clustering profile of cytokines was similar between DF and DHF,
cytokines IL-1b, IL-4, IL-6, IL-8, IFN-c, IL-17, G-CSF, VEGF, IP-
10, and PDGF-BB (marked by asterisk in Figure 1F) either clustered
differently or showed different slopes (not shown) between the
disease stages in DF and DHF groups suggesting that there may be
changes in the temporal profile of these cytokines.
Overall, our results indicated that cytokines and chemokines
associated with innate immune activity (e.g. IFN-c, IP-10), Th2
cell response (IL-4, IL-10, and IL-13), inflammation (IL-1b, IL-6,
and IL-8), chemotaxis of macrophages and neutrophils (Eotaxin,
MIP-1b) are all maximally elevated in dengue patients during the
early febrile phase. Cytokines IL-12, growth factors FGF and
PDGF increased even at convalescence. TNF-a remained below
detection levels in our analysis likely because production is
transient and missed in our timeline of sample collection.
Similarly, levels of IL-2, IL-15, GM-CSF and MIP-1a were below
the detection limit in .85% of the samples and were excluded
from further analysis.
Early cytokine responses distinguish DF from DHF
Differences in temporal profile of a subset of cytokines between
DF and DHF patients, identified in the clustering analysis outlined
above, prompted us to examine these cytokines more closely across
different time points of infection in DF and DHF groups. We
observed that DHF patients had lower levels of IFN-c during
febrile phase, a time of peak interferon activity (Figure 2A–B).
Although levels of IP-10 (an interferon-induced cytokine) were also
lower in the DHF group, this was statistically significant (p,0.05)
only at defervescence (Figure 2B). Low levels of IFN-c as well as
IP-10 during the febrile phase point to an attenuated interferon
response in DHF patients, which may be associated with
diminished viral clearance. There was a marginal but significant
correlation between viral titers and IFN-c levels during the early
febrile stage (visit-1, (r = 0.370; p,0.05). The correlation was
especially strong between IFN-c at visit-1 and IP-10 at visit-2 in
DHF patients (r = 0.66; p,0.05).
We observed decreased levels of Th2 cytokine IL-4, in DHF
patients during the febrile stage, (Figure 2C) compared with DF.
Unlike DF patients, IL-1b levels in DHF patients were indistin-
guishable from healthy controls until the convalescence stage,
indicating a depressed IL-1b response (Figure 2D). Levels of IL-17
as well as Granulocyte-Colony Stimulating Factor (G-CSF) were
lower in DHF patients especially during the febrile stage (Figure 2E
and F). The serum profiles for platelet-derived growth factor
(PDGF-BB) as well as vascular endothelial growth factor (VEGF)
were similar to G-CSF and markedly lower during the febrile
phase in DHF patients compared to DF patients (Figure 2G, H). A
similar comparison of other cytokines IL-6 and IL-8 that were
found altered in the clustering analysis (Figure 1E &F) indicated
that the differences between DF and DHF groups were not
statistically significant (data not shown). The number of patients in
this study was too low to allow stratification by days from fever
onset (Figure S2).
Profiling of serum proteome flux during dengue
progression in humans
Quantitative proteomics by isobaric tagging of peptides allows
multiplexing of biological samples thereby reducing variability
while increasing accuracy of protein quantitation [17]. We
adopted an iTRAQ-based approach to quantify the serum
proteome of pooled dengue patient sera during the different
stages of the disease. Overall, we identified 90 proteins with high
confidence, and determined their fold-change over control
samples, in both DF and DHF patient groups (Table 2). Of a
total of 35 proteins that showed a .1.5 fold enrichment or
depletion, 25 proteins were unique to DHF patient group while 6
proteins - serum amyloid A2, leucine-rich-alpha-2 glycoprotein,
hemoglobin alpha, actin, haptoglobin and alpha-1-antitrypsin,
changed in both DF and DHF samples (Table 2). The acute phase
reactants were the most abundant class, followed by serpin class of
protease inhibitors and complement pathway proteins (Figure 3A).
A majority of these proteins were maximally elevated during the
febrile phase although some remained high or increased further
during defervescence (Table 2). Five proteins were depleted from
sera during the febrile and defervescence stage but returned to
near control levels during the convalescent stage (Table 2).
Overall, the proteomic analysis indicated that the most readily
observable predominant serum protein response in dengue
infections was the acute phase response.
A major caveat of the sample pooling approach described above
is the averaging effect which may result in a gross underestimation
of fold changes despite the high accuracy and sensitivity of the
proteomic quantification. As an alternative, we used a commer-
cially available multiplex fluorescent-bead based ELISA assay,
which simultaneously measures levels of 9 well-known acute phase
proteins including two serum proteins (serum amyloid A2 (SAA)
and haptoglobin (HPT)) that were identified in our proteomics
analysis (Table 2). Using this method, we analyzed individual
serum samples from 10 DHF, 24 DF patients and 10 healthy
asymptomatic controls. SAA and HPT were elevated in dengue
patients during the early febrile (visit-1) and defervescence (visit-2)
stages (Figure 3B–C). Other acute phase proteins that were
elevated in dengue patients included C-reactive protein (CRP),
alpha-2 macroglobulin (A2M) and ferritin (FT) (Fig. 3D–F), while
serum amyloid P (SAP), pro-calcitonin (PCT), tissue plasminogen
activator (t-PA) and fibrinogen (FB) remained unchanged (not
shown). With the exception of SAA, which was higher in DHF
patients during the febrile phase, the differences in levels of other
proteins between DF and DHF patient groups were not
statistically significant.
Markers of neutrophil and macrophage activity are
elevated in dengue patient sera
We used a previously established mass spectrometry based
method [18] to measure levels of total serum 3-nitro-tyrosine (NT)
Serum Markers of Dengue Disease Progression
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Figure 2. Early cytokine responses distinguish DF and DHF patients. A subset of eight cytokines that exhibited different clustering between
DF and DHF patient groups were examined individually. Mean values of IFN-U (A), IP-10 (B), IL-4 (C), IL-1b (D), IL-17 (E), G-CSF (F), VEGF (G) and PDGF-
BB (H) from patients (44 DF; 18 DHF) are plotted. Statistical confidence (p,0.05) was analyzed by ANOVA kruskall-wallis test (DF vs DHF: *p,0.05,
**p,0.01, ***p,0.001, NS- not significant); dengue (DF or DHF) vs. healthy control: 111p,0.001, 11p,0.01, 1p,0.05, # not significant). Standard
deviation from mean across populations is shown in the error bars (upper deviation only).
doi:10.1371/journal.pntd.0001887.g002
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Table 2. Serum proteome changes in dengue patient sera across different stages of disease.
Protein Uniprot ID Peptides Functional Class* Fold Change (DF/DHF)
Febrile Deferv. Conval.
Elevated levels in sera during acute infection
Serum Amyloid A2** P02735 3 ACR, HDL 3.4/11.4 1.9/4.7 1.0/1.4
Leucine-rich-alpha-2 glycoprotein** P02750 8 Unknown 2.0/6.4 1.3/3.6 0.9/2.5
Hemoglobin subunit-alpha** P69905 4 RBC 1.9/5.9 0.8/1.0 0.8/1.1
Actin, cytoplasmic** P60709 2 cytoskeleton 2.1/4.2 2.2/7.3 1.2/2.6
Hemoglobin subunit delta P02042 5 RBC 1.2/4.1 0.9/2.8 0.8/1.3
Insulin-like growth factor-binding protein 3 P17936 7 carrier 1.2/4.0 1.2/3.4 1.0/4.2
Hemoglobin subunit-beta P68871 5 RBC 1.3/4.0 0.8/2.0 0.7/1.0
Phosphatidyl-inositol glycan specific
phospholipase-D
P80108 7 GPI-anchor cleavage 1.2/3.8 0.9/4.0 1.0/2.2
Plasma protease C1 inhibitor P05155 6 ACR, Comp 1.4/3.8 1.7/5.0 1.0/2.6
Hemoglobin subunit zeta P02008 11 RBC 1.0/3.5 1.1/1.1 0.9/0.7
Coagulation factor XII P00748 4 Coagulation 1.3/3.4 1.3/4.2 1.3/3.7
EGF-containing fibulin-like ECM protein Q12805 4 EGF regulation 1.0/2.9 1.5/2.8 0.9/3.0
Alpha-1B-glycoprotein P04217 10 Unknown 1.3/2.8 1.2/3.3 1.1/2.8
Tumor protein 63 Q9H3D4 3 DNA-binding 1.5/2.8 0.8/2.5 0.8/3.8
Alpha-2 antiplasmin P08697 4 ACR, SERPIN 1.2/2.7 1.6/2.5 1.3/2.5
Alpha-1-antichymotrypsin P01011 18 ACR, SERPIN 1.3/2.5 1.4/2.6 0.8/1.4
Hemopexin P02790 18 Heme transport 1.0/2.5 0.9/1.8 1.0/1.7
Transthyretin P02766 4 Hormone binding 0.8/2.4 0.7/0.6 1.3/3.2
Complement C4-A P0C0L4 34 ACR, Comp 1.3/2.4 1.6/2.2 0.9/1.8
Complement component C9 P02748 4 ACR, Comp 1.5/2.3 1.2/2.9 0.9/1.5
Inter-alpha-trypsin inhibitor H3 Q06033 6 Hyaluronan-bind 0.4/2.3 1.1/2.8 1.3/2.3
Alpha-1-acid glycoprotein 1 P02763 6 ACR 1.5/2.3 1.4/2.2 0.8/1.0
Haptoglobin** P00738 26 ACR 4.1/2.2 2.0/2.9 2.0/1.5
Antithrombin-III P01008 17 ACR, SERPIN 1.2/2.2 1.4/3.2 1.1/1.9
Inter-alpha-trypsin inhibitor H2 P19823 19 Hyaluronan-binding 0.8/2.2 0.7/1.9 1.0/2.4
Apolipoprotein A–I P02647 32 HDL 0.7/2.1 0.9/1.1 0.7/1.5
Serum Paraoxonase/arylesterase 1 P27169 7 HDL 1.0/2.1 1.0/2.1 1.1/1.9
Apolipoprotein E P02649 15 LDL, HDL 1.3/2.0 1.2/2.8 1.5/2.3
Corticosteroid-binding globulin P08185 4 SERPIN 0.9/2.0 0.8/1.9 0.9/1.8
Alpha-1-acid glycoprotein 2 P19652 5 ACR 1.4/2.0 1.4/2.7 1.4/1.3
Haptoglobin-related protein P00739 3 ACR,SERPIN 1.2/2.0 1.5/1.5 0.9/1.0
Clusterin P10909 12 Chaperone 1.0/2.0 1.0/2.4 1.2/2.2
Alpha-2-HS-glycoprotein P02765 10 ACR 1.1/2.0 1.3/1.8 0.9/2.4
Alpha-1-antitrypsin** P01009 20 ACR, SERPIN 1.5/1.9 2.2/3.3 1.1/1.2
Depleted in sera during acute infection
Apoliprotein CI P02654 2 VLDL 0.3/1.05 0.4/0.9 0.7/1.9
Apoliprotein CII P02655 3 VLDL 0.4/1.3 0.6/1.6 1.1/2.6
Apoliprotein CIII P02656 2 VLDL 0.5/0.8 0.6/0.8 1.1/1.2
Apoliprotein CIV P55056 2 VLDL 0.17/2 0.8/2 0.9/2
Platelet basic protein P02775 3 Platelet cytokine 0.5/1.2 0.4/0.8 1.0/2.0
*Functional class obtained from Uniprot database (www.uniprot.org); ACR-Acute phase reactant, SERPIN- Serine protease inhibitor, LDL-Low density lipoprotein, HDL-
High density lipoprotein, Comp- Complement pathway.
**indicates proteins that changed .1.5 fold in both DF and DHF samples during the febrile or defervescence stage. Fold change – refers to ratio of mass ion (115 –visit-
1, 116-visit2, 117-visit-3) intensities over the 114 mass ion intensity representing a reference control sample (see methods) Febrile stage corresponds to visit-1, Deferv. –
visit-2, Conval.-visit-3. DF- dengue fever, DHF- dengue hemorrhagic fever.
doi:10.1371/journal.pntd.0001887.t002
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and 3-chloro-tyrosine (CT), in 44 DF patients and 10 DHF
patients at three different stages of the disease. Compared to
healthy individuals where CT and NT levels in sera are below
detection, there was a significant elevation of both CT and NT in
dengue patient sera (Figure 4). Levels of CT were elevated in all
dengue patients during the febrile phase compared to controls, and
continued to increase during defervescence and remained high at
convalescence (Figure 4A). This suggests that neutrophil activity
remains high even after viral clearance. Interestingly, DHF
patients displayed higher levels of CT compared to DF patients
during the early febrile phase and although higher levels were also
seen during defervescence and convalescence, the differences at
the latter stages were not statistically significant (at p,0.05). NT
peaked during the early febrile phase of the infection but declined
to near basal levels during the convalescence stage (Figure 4B). We
did not observe statistically significant (p,0.05) differences in NT
levels between DF and DHF groups in our experiment.
Multivariate analysis reveals predictive markers of DHF
We adopted a multiple-feature selection strategy to identify
subsets of features from among the 47 blood parameters described
above that may have predictive value in the identification of DHF
during the early febrile phase. By analyzing the various feature
classes (i.e. cytokines, serum proteins, protein adducts, and clinical
features) measured at the early febrile phase (visit-1), both
independently, as well as together we evaluated the relative
predictive power of these various molecules. First, we analyzed 23
cytokines and identified a subset of 7 cytokines which displayed
sensitivities and specificities .75% (Table 3). A receiver operator
characteristics (ROC) curve analysis indicated that this subset
performed well with area under curve (AUC) of 0.8760.05
(Table 3, Figure 5). We next combined 15 laboratory clinical
features (listed in the methods section) along with the cytokines and
reanalyzed the data. This resulted in a new subset (Table 3) and
achieved sensitivities and specificities .80% with an AUC of
0.9260.03 (Table 3, Figure 5). While cytokines IFN-U, IL-1b, IL-8
and IL-17 were common with subset A, combining them with
lymphocyte, platelet counts and viral titers improved the predictive
performance of subset-B compared to subset-A (Table 3). The
addition of two more features- CT and NT- to the dataset resulted
in a new subset that retained cytokines- IFN-U and IL-1b, IL-8,
and blood lymphocyte count, but also had additional set of
cytokines (Table 3) along with CT. However, overall predictive
performance of subset group-C was poorer likely due to reduction
of population size (n = 54 as compared with n= 62).
Finally, we expanded the dataset to include all measured
features (i.e. 23 cytokines, 5 serum proteins, 2 protein adducts and
15 clinical features). The number of patients in this analysis was
much lower (n = 34) than the previous analysis (n = 62 and n= 54)
due to further exclusion of samples where the data was incomplete
due to missing values. The subset from this analysis included a
variety of features including serum proteins (SAA and HPT),
cytokines (IFN-U, IL-17) and protein adducts (CT) that achieved a
sensitivity and specificity of .75% and AUC of 0.9060.06
(Table 3).
Discussion
We have performed a comprehensive molecular analysis of
serum molecules in a cohort of adults with primary dengue
Figure 3. Analysis of serum protein flux at different stages of dengue infections. A. Functional grouping of proteins identified in the
proteomics analysis (see Table 2) shown as a pie chart with percent of total proteins (n = 35) identified within each group. B–F. Levels of 9 acute phase
reactants measured in sera from 24 DF, 10 DHF patients and 10 healthy control samples using a multiplex assay. Levels of serum amyloid A2 (SAA),
haptoglobin (HPT), C-reactive protein (CRP), ferritin (FT) and alpha-2-macroglobulin (A2M) shown in picogram per ml. ANOVA Kruskall-Wallis test-
dengue (DHF or DF) vs. Control (*p,0.05, **p,0.01, ***p,0.001, NS- not significant), DHF vs. DF within each time point (1 p,0.05,# not significant).
Febrile (visit-1), Deferv. (visit-2) Conval. (visit-3).
doi:10.1371/journal.pntd.0001887.g003
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infections with the objective of identifying predictive markers of
DHF. Traditionally, biomarkers studies have relied mostly on case
versus control studies (reviewed in [6]) with one sample per
patient, collected in a 1–10 day period. Some of these studies have
reconstructed temporal profiles via data grouping based on fever
day [19,20,21]. However, variability in sample size within groups
(e.g. fever day) and lack of patient follow-up often result in poor
statistical performance and inadequate modeling of individual
immune responses. Prospective follow-up of patients across disease
stages, although most desirable for biomarker development, are
scarce. A good example is a 1997 pediatric dengue study in
Thailand, where a positive dengue diagnosis was followed by daily
blood sampling till one day post defervescence [22,23]. The
EDEN study combines the convenience of asynchronous patient
recruitment during the early febrile phase, with patient follow-up,
and is designed to specifically model adult dengue infections [7].
A detailed cytokine analysis indicated that DHF patients are
characterized by an attenuated serum cytokine response especially
during the early febrile phase. In DHF, low levels of IFN-c during
febrile phase correlated with reduced levels of IP-10, indicating
that an inability to mount a timely anti-viral response may result in
high viremia. In cell culture models, pretreatment with interferons
inhibits dengue viral replication [24] although treatment after
infection has no effect due possibly to active inhibition of IFN-
signaling pathways by dengue viral protein NS4B [25]. Whether
higher viral titers reported in DHF patients is a consequence or
cause of an impaired interferon response remains to be confirmed.
In recent human challenge studies, development of infection
Figure 4. Markers of macrophage and neutrophil activity are in dengue patient sera. Total serum CT (A) and NT (B) levels in dengue
patients during febrile, defervescence and convalescence stages. Levels of CT and NT measured in 15 healthy samples was found to be below
detection limit (not shown). Statistical confidence was analyzed by ANOVA kruskall wallis-test, DF vs DHF (**p,0.01, NS- not significant).
doi:10.1371/journal.pntd.0001887.g004
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correlated with extremely low or undetectable IFN-c production
by PBMCs suggesting a role for sustained IFN-c production in
protection [26]. An attenuated innate response may in turn affect
the kinetics of adaptive immune and pro-inflammatory responses,
as suggested by the lower levels of Th2 cytokines IL-4 and IL-13,
growth factors G-CSF, VEGF and PDGF, observed during the
febrile stages in DHF patients in this study.
In contrast our findings, a number of previous studies have
reported elevated levels of IFN-c [19], IL-8 [27], IL-6, TNF-a
[28], MIP-1b [19], IL-10 [29], and free VEGF [23], in DHF
Figure 5. Multivariate statistics reveals predictive serummarkers for early classification of DHF. A. Receiver operator characteristic curve
(ROC) analysis of subset groups A (cytokines only), B (cytokines+clinical indicators) and C (cytokines+clinical indicators+protein adducts) (see table-3
for subsets) is shown. Area under curve (AUC), values of .0.85, indicated good performance (see methods) with high sensitivity and specificity.
doi:10.1371/journal.pntd.0001887.g005
Table 3. Identification of serum molecules for early classification of DHF.
Subset group Type of features Specific features4 Sensitivity %* Specificity %* AUC*




B 23 Cytokines1 IFN-U, IL-1b, IL-17,
IL-8,
80(11) 86(7) 0.92(0.03)
19 Clinical features1 G-CSF, LYMPH, PLT,
Viraemia
C 23 Cytokine2 IFN-U, IL-1b, IL-8,
IL-9,
71(18) 85(7) 0.88(0.05)
19 Clinical Features2 IL-1ra, G-CSF, Eotaxin,
2 Protein Adducts2 CT, LYMPH, Viraemia
D 23 Cytokines3 IFN-U, IL-17,
FGF-basic,
83(14) 75(13) 0.90(0.06)
19 Clinical features3 RANTES, IP-10, CT,
2 protein adducts3 LYMPH, SAA, HPT
5 Serum proteins3
1n = 62 (44 DF; 18 DHF);
2n = 54 (44 DF; 10 DHF);
3n = 34 (24 DF; 10 DHF);
4All measurements are from febrile stage (visit-1); Mean (SD) values shown; AUC-area under curve from receiver operator characteristics analysis. DHF - dengue
hemorrhagic fever. Please see methods section for details on feature selection.
doi:10.1371/journal.pntd.0001887.t003
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patients. However these studies differ significantly from the present
study in the types of clinical cohorts evaluated. For example,
comparable longitudinal cohort studies reporting higher levels of
IL-10 and IL-6 have focused exclusively on pediatric cases [29,30].
Importantly, primary infections made up less than ten percent of
the cohorts in previous studies reflecting the higher incidence of
DHF in secondary infections. Hence, different cytokine profiles
observed in the present and previous studies are likely related to
differences in immune responses to primary and secondary
infections. The few studies that have included a subset of primary
infections have reported conflicting results, with some reporting
higher levels of cytokines in secondary compared to primary
infections [31,32], while others reporting no differences [33]. It is
noteworthy that no DHF patients were included in these studies,
and therefore it is not possible to compare cytokine profiles specific
to DHF. We hypothesize that timely interferon-regulated antiviral
responses are critical determinants of outcome in primary
infections, whereas inflammatory mediators and regulators of
antibody-dependent enhancement, including IL-6, IL-8, and IL-
10 may dominate in secondary infections. Ethnic background of
patients can also affect the type of cytokine responses to dengue
infections [34], and may contribute to cytokine profiles described
here.
In an attempt to identify serum protein markers of DHF, several
groups have reported proteomic analysis of dengue patient sera
[35,36,37]; using a variety of methods and clinical cohorts. We
used a highly sensitive isobaric-tag method of quantitation that
allowed us the compare the proteomic changes across different
stages of infection. We focused on the most prominent functional
protein group identified (i.e. acute phase reactants), and observed
elevated levels of CRP, SAA, HPT, A2M and FT in individual
patient samples. Maximum elevation of CRP and SAA in the early
febrile phase was consistent with elevated production of IL-6, a
hepatic inflammatory cytokine. Interestingly, acute phase reactants
PCT, FB and SAP were not altered, and this may be related to
liver dysfunction observed in dengue patients [38]. With the
exception of SAA, there were no significant differences between
DF and DHF groups suggesting that acute phase response is not a
dominant mechanism of pathology in primary infections. Under-
standing the specific functional role of other proteins shortlisted in
our proteomics study will require detailed validation.
Nitric oxide (NO) production by phagocytes is an important
inflammatory response to pathogens and although increased levels
of both inducible NO synthase (iNOS) and NO levels have been
reported in dengue patients [28,39], their role in dengue viral
clearance is unknown. Protein adducts CT and NT formed from
NO-mediated reactions are sensitive surrogate measures of
neutrophil and macrophage activities during inflammation
[18,40]. We observed elevated levels of CT in dengue patient
sera compared to healthy controls, which continued to rise from
early febrile to defervescence stage indicating robust and sustained
neutrophil activity. Interaction of activated neutrophils with the
endothelium has been known to modulate vascular permeability
[41,42]. Whether elevated levels of CT can serve as an early
indicator of plasma leakage remains to be tested. In contrast to
CT, the transient nature of NT accumulation suggests that
macrophage activity is limited to the acute phase of the infection,
possibly linked to viral titers.
The comprehensive database of 47 blood parameters from
dengue patients described in this study provides a unique
opportunity to statistically query this dataset to identify -1) most
significant molecules and 2) their relative importance in distin-
guishing DHF from DF during the early febrile stage. In the final
analysis, a subset of 9 features was identified that included 5
cytokines, chlorotyrosine, blood lymphocyte count, and two serum
proteins. Overall, cytokines involved in attenuated antiviral
response; up regulation of acute phase proteins, and elevated
neutrophil activity; together appear to be early signatures of DHF
resulting from primary infections. The precise role of other
cytokines IL-17, FGF-basic, and RANTES that were included in
the predictive subset, in DHF pathogenesis is currently unclear
and does not rule out the involvement of other cytokines in
regulation of immune mechanisms in DHF patients.
Previously, a variety of statistical methods including classifica-
tion and regression tree (CART) analyses [43,44], as well as
decision tree algorithms [45] have been used to identify clinical
markers that achieved high sensitivity but poor specificity in
classification of DHF. These clinical parameters, however, require
daily monitoring. Identifying and measuring the molecules that are
directly involved in pathogenesis could improve our predictive
capabilities. Recently, Brasier et al used a logistic regression
approach to report a 3 component biomarker panel consisting of
platelet count, lymphocyte count and IL-10 that, classified DF
from DHF patients with an accuracy of .85% during the first
week following onset of fever [21]. In a second study Brasier et al
used a multivariate adaptive regression splines (MARS) method to
evaluate cytokines and plasma proteome from a cohort of
secondary dengue infections and reported a panel consisting of
IL-10 and seven serum proteins that achieved 100% sensitivity
and specificity in prediction of DHF in the first week of fever onset
[37]. However, these two studies applied a broad window of
measurement, which may not capture the dynamic processes of
DHF pathogenesis. It also raised the possibility that biomarkers of
DHF in secondary infections may be qualitatively and quantita-
tively different from primary infections. Determining which of
these biomarkers reflect differences in primary versus secondary
infections and which inform on DHF development, whether in
primary or secondary infections, will be critical for the develop-
ment of robust biomarkers to stratify dengue patients for medical
care.
In conclusion, this study describes a comprehensive and
systematic molecular analysis of serum samples from a cohort of
patients with primary dengue infection. The analytical approach
and statistical workflow we have outlined forms a robust platform
for both future discovery and validation of biomarkers for
prediction of severe dengue disease.
Supporting Information
Figure S1 Serum cytokine profile in dengue patients
during early febrile, defervescence and convalescent
stages of infection. 27 cytokines measured in sera from 62
dengue patients (44 DF+18 DHF) and 50 asymptomatic healthy
controls. Each graph shows data for an individual cytokine plotted
as mean values with standard deviation shown in error bars (upper
only). Statistical confidence (p,0.05) was analyzed by ANOVA
kruskall-wallis test, Dengue vs. healthy control (*p,0.05,
**p,0.01, ***p,0.001, NS- not significant).
(TIF)
Figure S2 Cytokine profiles in dengue patients grouped
by fever day. Samples from the study population were grouped
based on the day post onset of fever on which the samples were
collected for both DF and DHF groups. A. The number of samples
per group for the first seven days and total number of samples for
the period 15–30 days post onset of fever are plotted. The days are
further annotated to indicate the febrile (visit-1), defervescence
(visit-2) and convalescence (visit-3) phases. The levels of select
cytokines were also evaluated within these groups and included
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IFN-U (B), IL-4 (C), IL-1b (D), IL-17 (E) and IL-6 (F). The
ANOVA-Kruskal-Wallis test was used to determine confidence
levels. DF vs DHF: (* p,0.05, NS- not significant (p.0.1)).
(TIF)
Figure S3 Community feature selection strategy for
comprehensive evaluation of statistical performance of
multiple algorithms. A novel approach was developed to
identify predictive biomarkers for dengue disease. This approach
involved processing of data through a variety of feature selection
methods, each of which generate a shortlist of feature-subsets with
varying predictive performance. A ‘subset evaluation’ strategy
selects the best subset based on ‘average weighted cost’ following
which, hypothesis testing and significance criteria are used to select
the ‘best method’.
(TIF)
Table S1 Serum cytokine levels at various stages of
dengue disease in DF and DHF patients.
(DOCX)
Table S2 Serum cytokine kinetics in DF and DHF
patients compared with healthy individuals.
(DOCX)
Checklist S1 Strobe checklist.
(DOCX)
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